Entry comments: XGPT pick. News - Onconova Therapeutics’ Preclinical Narazaciclib Data at SABCS Highlights Differentiated Anti-Tumor Activity v. Other CDK4/6i’s. Consolidation Days: 61 - The stock shows strong consolidation behaviour after the specified number of days since the last breakout. This suggests that the stock may have ended its consolidation phase and is ready to break out. Goal 10-12% Profit.
Exit comments: XGPT continues to show this as a pick verdict day after day. Volume just isn't there. Held on for the week. Taking a small loss now.
Broker:ETrade
| Date | Price | |
|---|---|---|
| Entry | 12/11/2023 | 0.7916 |
| Exit | 12/15/2023 | 0.7363 |
- Total Views100
- Position Size1,500
- Percentage-6.99%
Proof
Copy and paste the following into your page or blog. If using WordPress, you must paste this in the HTML tab only:
